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Naturally occurring and man-made (synthetic) fibers of respirable sizes are substances that
have been identified by the U.S. Environmental Protection Agency (U.S. EPA) as priority
substances for risk reduction and pollution prevention under the Toxic Substances Control
Act (TSCA). The health concern for respirable fibers is based on the link of occupational
asbestos exposure and environmental erionite fiber exposure to the development of chronic
respiratory diseases, including interstitial lung fibrosis, lung cancer, and mesothelioma in
humans. There is also considerable laboratory evidence indicating that a variety of fibers of
varying physical and chemical characteristics can elicit fibrogenic and carcinogenic effects in
animals under certain exposure conditions. This paper discusses key scientific issues and
major default assumptions and uncertainties pertaining to the risk assessment of inhaled
fibers. This is followed by a description of the types of assessment performed by the U.S.
EPA to support risk management actions of new fibers and existing fibers under TSCA. The
scope and depth of these risk assessments, however, vary greatly depending on whether
the substance under review is an existing or a new fiber, the purpose of the assessment, the
availability of data, time, and resources, and the intended nature of regulatory action. In
general, these risk assessments are of considerable uncertainty because health hazard and
human exposure information is often incomplete for most fibers. Furthermore, how fibers
cause diseases and what specific determinants are critical to fiber-induced toxicity and
carcinogenicity are still not completely understood. Further research to improve our
knowledge base in fiber toxicology and additional toxicity and exposure data gathering are
needed to more accurately characterize the health risks of inhaled fibers. Environ Health
Perspect 105(Suppl 5):1329-1336 (1997)
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Introduction
A major goal ofthe U.S. Environmental
Protection Agency (U.S. EPA) is the pre-
vention, reduction, or elimination of
harmful pollutant releases into the general
environment. Naturally occurring and
man-made (synthetic) fibers ofrespirable
sizes are substances that have been identi-
fied as priority substances for risk reduc-
tion and pollution prevention. The health
concern for respirable fibers is based on
the link ofoccupational asbestos exposure
and environmental erionite fiber expo-
sure to the development ofchronic respi-
ratory diseases, including interstitial lung
fibrosis, lung cancer, and mesothelioma
in humans (1). Moreover, there is exten-
sive experimental evidence indicating
that a variety offibers ofvarying physical
and chemical characteristics can elicit
fibrogenic and carcinogenic effects in
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laboratory animals under certain exposure
conditions (2,3).
The U.S. EPA's Office of Pollution
Prevention and Toxics (U.S. EPA/OPPT)
is responsible for the evaluation ofhuman
health risk from occupational, consumer,
and environmental exposure to respirable
fibrous particles, and the development of
regulation under the Toxic Substances
Control Act (TSCA) to prevent, reduce, or
eliminate these potential risks. TSCA
authorizes the U.S. EPA to restrict or pro-
hibit the manufacture, processing, dis-
tribution, use, or disposal of chemical
substances already in commerce, and of
new substances when there is a reasonable
basis to conclude that any such activity
poses an unreasonable risk to human
health or the environment. TSCA also
empowers the agency to require the manu-
facturers and processors ofa chemical to
develop the necessary toxicity and exposure
data, ifthe agency determines that there is
significant human or environmental expo-
sure to such chemical, or that such chemi-
cal maypose an unreasonable riskbut lacks
sufficient data to take action. TSCA, how-
ever, requires the U.S. EPA to consider and
weigh health and environmental risks,
potential costs and benefits, and availability
ofalternative materials or technologies
before taking any riskreduction actions.
This article describes the risk assess-
ment approaches utilized by the U.S.
EPA/OPPT in characterizing human
health risks ofexposure to new and exist-
ing fibers i.e., fibers that are listed on the
TSCA inventory other than asbestos. This
paper begins with a briefoverview of the
general principles of human health risk
assessment and a discussion ofthe major
scientific issues, uncertainties, and default
assumptions pertaining to the risk assess-
ment of inhaled fibers, and of research
needs to improve the scientific basis for
future risk assessments. This is followed
by a description of the types of assess-
ment performed by the U.S. EPA/OPPT
to support risk management actions of
new fibers and existing fibers under
TSCA. Attention is focused on the kinds
of scientific information and key factors
that are considered in the hazard and
dose-response assessments of the risk
assessment process. Exposure assessment is
only briefly addressed. The risk assessment
ofasbestos conducted by the U.S. EPA
will not be discussed here, as it can be
found elsewhere (4).
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General Principles
of Risk Assessment
Risk assessment involves the analysis and
synthesis ofthe entire knowledge base on
an environmental agent to characterize the
anticipated risk from human exposure to
the agent. The U.S. EPA has followed the
basic National Research Council risk assess-
ment paradigm (5,6) as a foundation for its
human health risk assessment guidance
(7-9). Risk assessment consists of four
components: hazard identification, dose-
response relationship assessment, exposure
assessment, and riskcharacterization.
The U.S. EPA's risk assessment
guidelines contain detailed guidance on the
application ofdefault assumptions, i.e., sci-
ence policy choices, and the associated
uncertainties. It is generally accepted that
default assumptions are necessary tools in
performing risk assessment to bridge the
gaps in general scientific knowledge and in
data for a particular agent. Default assump-
tions are developed generically, not on an
agent-by-agent basis. The intent is that
default positions are taken for all agents
unless case-specific data clearly indicate
that the default assumption is no longer
plausible and another inference position
may be more appropriate.
Hazard identification is a qualitative
assessment of available scientific data to
make an informed judgment about the
potential adverse human health effects
posed by an agent. The principal question
is what is known about the capacity ofan
environmental agent for causing adverse
effects in humans, and under what expo-
sure conditions an identified adverse effect
may be expressed. The U.S. EPA uses a
weight of evidence (WOE) approach to
evaluate the potential human health effects
of an agent. Information for this WOE
evaluation is derived from available studies
in humans and laboratory animals on the
agent and on structurally related sub-
stances, together with other relevant infor-
mation such as chemical and physical
properties, toxicokinetic data, results of
short-term assays for biochemical, molecu-
lar, genetic, and cellular effects, and any
other mechanistic data.
Because human data are not always
available, most hazard evaluations are, of
necessity, based on animal data. Con-
sequently, a major default assumption in
hazard assessment is that an agent causing
adverse effects in laboratory animals will also
have the potential to cause adverse effects in
humans unless the available data prove oth-
erwise. In addition, in the absence of
evidence to the contrary, data from animal
studies in the most sensitive animal species
are used for dose-response assessment pur-
poses. The underlying scientific basis for
this default assumption is the possibility that
human sensitivity is as high as the most
sensitive respondinganimal species.
The dose-response assessment evalu-
ates the quantitative relationship of expo-
sure and dose to the degree ofresponse in
existing studies in which adverse health
effects have been observed. When environ-
mental exposures of interest are outside
the range of observation, extrapolations
are necessary to estimate the likelihood of
adverse effects in populations potentially
at risk, if it is deemed appropriate and
scientifically supportable.
Because cancer and noncancer effects
historically are believed to occur by differ-
ent modes of action, different approaches
to dose-response relationship assessment
have been developed. It is believed that
most cancers, ifnot all, develop as a conse-
quence of mutations of critical genes.
Because a single chemical-DNA interac-
tion may lead to a mutation, and because
cancer is thought to arise from single cells,
it follows that any dose ofan agent may be
associated with some finite risk. This has
led the agency to employ a default proce-
dure that cancer risk should be estimated
by a linear, nonthreshold dose-response
approach when the mode of action is not
known, supportive oflinearity, or is insuf-
ficient to support a nonlinear or threshold
mode of action (8). It is recognized that
such extrapolation does not necessarily give
a realistic prediction ofthe risk but is con-
sistent with the agency's goal to provide an
estimate ofthe upper limit to risk.
In contrast, based on our understanding
ofhomeostatic and adaptive mechanisms,
the default approach for dose-response
assessment of noncancer toxicity, i.e.,
toxicity other than cancer and gene muta-
tions, assumes an identifiable threshold
below which effects are not observable
(10,11). It should be noted, however, that
future case-specific knowledge of the
mechanisms ofchemically induced toxicity
and carcinogenicity may blur this distinc-
tion between approaches for noncancer
toxicity and carcinogenicity.
The exposure assessment identifies the
likely sources ofhuman exposures to the
environmental agent, environmental path-
ways for exposure (e.g., air, water, soil,
food), potential routes of exposure (e.g.,
oral, dermal, inhalation), populations at
risk, including those of highly exposed
groups and highly susceptible groups, and
estimates exposure and dose levels that
impact the exposed individuals or popula-
tions. The exposure assessment relies on
many kinds ofinformation, some based on
actual measurements and some developed
usingpredictive models and surrogate data.
Risk characterization, the last step in risk
assessment, is the integrated analysis ofthe
preceding three steps in risk assessment to
reach a conclusion about the nature and
magnitude ofexpected risk. The predicted
risk can be qualitative (e.g., high or low
probability) or quantitative (e.g., one in a
million probability of occurrence). Risk
characterization also includes a discussion of
the confidence, limitations, and uncertain-
ties ofthe risk assessment, given the con-
straints ofavailable data, and the state of
scientific knowledge, significant issues, and
scientific assumptions and policychoices.
It should be noted that not every U.S.
EPA risk assessment contains all four com-
ponents. The scope and depth of the risk
assessment depend on the availability of
scientific data, resources, and time, the
purpose ofthe assessment, any legislative
mandates, and the nature of the intended
regulatory action.
Issues in Risk Assessment
of Inhaled Fibers
The following section discusses some key
scientific issues and uncertainties to be kept
in mind when assessing the potential
health risk from exposure to fibers. These
include a) the incomplete knowledge of
how certain mineral fibers cause disease in
humans and laboratory animals and which
specific fiber properties are important in
influencing their biologic and toxicologic
effects; b) the limitations of available
experimental models to accurately predict
adverse outcomes in humans; and c) the
lack ofreliable data on human exposures to
a wide variety types offibers of concern.
All ofthese factors contribute in part to the
uncertainties ofthe risk assessment process.
MechanismsofFiber-induced
ToxicityandCarcinogenicity
Although there have been significant
advances in our knowledge about the
health effects ofasbestos and other fibers in
recent years, the mechanisms by which
mineral fibers cause fibrogenic and car-
cinogenic effects in humans and laboratory
animals are not clearly understood. Fiber-
induced fibrogenesis appears to arise from a
chronic inflammation process that involves
the release of cellular mediators (e.g.,
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lysosomal enzymes, arachidonic acid
metabolites, neutral proteases, cytokines,
growth factors, chemotactic factors, or
reactive oxygen species [ROS]) by activated
alveolar macrophages and other inflamma-
tory cells. These events are believed to be
followed by the proliferation of fibrolasts
and deposition of collagen within the
alveolar spaces and the interstitium.
With regard to fiber-induced carcino-
genicity, several hypotheses have been pro-
posed. These include: a) DNA damage by
ROS induced by fibers; b) direct DNA
damage by physical interactions between
fibers and target cells; c) enhancement of
cell proliferation by fibers; d) fibers that
elicit a chronic inflammatory reaction,
which leads to prolonged release of ROS,
cytokines, and growth factors; and e) fibers
that act as cocarcinogens or carriers of
chemical carcinogens to the target tissue. It
is likely that all ofthese mechanisms con-
tribute to the carcinogenicity of fibers
because all these effects have been observed
in various in vitro systems ofhuman and
mammalian cells using different types of
fibers (12).
The role of fiber-induced fibrosis in
carcinogenesis is not clear. Macrophage
lysis and chronic inflammation induced
by fiber exposure may not only lead to
lung fibrosis but also to the development
of some lung tumors in rats. Other rat
lung tumors, however, appear to have no
relationship to fibrotic scar.
Critical Determinants ofFiber
ToxicityandCacinogenicity
Current scientific knowledge indicates that
a major determinant of fiber toxicity and
carcinogenicity is fiber dimension. There is
extensive evidence relating to the impor-
tance of fiber size in lung deposition and
clearance offibers, which in turn govern
the bioavailability offibers at target tissues
(13). Fiber diameter is the major determi-
nant for the deposition of fibers. Only
fibers less than about 3.5 pm in diameter
can reach the alveolar spaces. Fiber length
also influences the deposition and clearance
of fibers. Fibers longer than 20 pm are
more readily deposited by interception at
airway bifurcations. In general, short fibers
(< 5 pm) are cleared more rapidly than
long fibers (> 5 pm). Fiber size also plays
an important role in relation to cellular
mechanisms of toxicity and carcinogenic-
ity. Long fibers of a given fiber type are
generally more biologically active than
shorter fibers, regardless of the measured
biological end points such as cytoxicity,
cell transformation, or aneuploidy.
Furthermore, long fibers (>5 pm) are more
carcinogenic and fibrogenic than short
fibers ofasbestos and other fibers (<5 pum)
in chronic studies in rats by inhalation
(14,15) or intracavitary injection (2,3).
Fiber biopersistence may also be an
important determinant offiber toxicity and
carcinogenicity. The concept ofbiopersis-
tence arose from the observation that differ-
ent natural and synthetic fibers have
different lung retention characteristics; some
persisting over long periods, others being
less persistent. It has been hypothesized that
a fiber with critical dimensions will be car-
cinogenic if it is sufficiently durable to
remain chemically and physically intact in
lung tissue in close contact with the target
cells (3). Although more durable fibers
appear to be more carcinogenic than more
soluble fibers e.g., refractory ceramic fiber
(RCF) versus glass fiber, neither the influ-
ence ofbiopersistence on fibrogenesis and
carcinogenesis nor the length of time
required for a fiber to remain in the lung to
exert a pathogenic effect has been ade-
quately defined. For instance, chrysotile
asbestos fiber is significantly less biopersis-
tent than amphibole asbestos, yet the fiber
is clearly carcinogenic and fibrogenic in
humans. In view of the many different
mechanisms bywhich fibers might influence
the carcinogenic process, it is difficult to
determine the degree ofbiopersistence nec-
essary for fiber carcinogenicity. In addition,
available models offiber solubility or dura-
bility in physiological systems, as well as
fiber biopersistence in the lung, remain to
be validated. Nevertheless, it is generally
believed that fibers capable ofbiopersistence
in the lung are ofgreater concern.
Other fiber characteristics such as
surface area, chemistry, and chemical
leaching are also likely to play a role in
fiber-induced toxicity and carcinogenicity,
although these are much less well under-
stood. For example, acid-leached chrysotile
fibers are less carcinogenic than native
fibers (16).
DefinitionofFibersofConcern
A major issue for the U.S. EPA is to
define the category offiber ofconcern. As
discussed above, it is recognized that there
are a number offiber properties e.g., fiber
size, chemical composition, biopersis-
tence, and surface chemistry that are likely
to exert an influence on the pulmonary
toxicity and carcinogenicity of inhaled
fibers. However, it is the presence of a
long thin fibrous shape that appears to be
the most important determinant offiber-
induced pathogenicity. Still, it is not
known whether there is any single cutoff
of fiber length or diameter that implies
human safety. Moreover, the conventional
definition of a fiber used for industrial
hygiene purposes continues to be a
practical index for risk assessment.
Consequently, fibrous particles of res-
pirable sizes are considered potentially haz-
ardous unless there are available data to
demonstrate otherwise.
For regulatory purposes, the U.S. EPA
defines fiber as a particle oflength >5 pm
with an aspect ratio (ratio offiber length to
fiber diameter) ofat least 3:1 (4). This def-
inition has been widely adopted by other
organizations (17,18). Fibers with aero-
dynamic diameters of 10 to 12 pm or less,
or actual fiber diameter ofabout 3.0 to 3.5
pm or less, are generally considered res-
pirable for humans (19). The upper limit
of fiber length for human respirability is
about 200 pm (20). This definition applies
to any particle that fulfills these criteria
regardless of chemical composition or
mineralogic characteristics.
ExposureCharterization
Given that fiber exposure characteristics
greatly influence the nature ofthe hazard, it
is essential that human exposures to fibers
are measured to the extent feasible and fully
characterized (e.g., airborne fiber dimen-
sions and physicochemical characteristics,
fiber concentrations per unit air volume,
frequency and duration ofexposure) to per-
mit a more reliable characterization of
potential human risk. Available data on
human exposures to fibers, however, are
often limited. Furthermore, standard ana-
lytical methods to characterize and monitor
fiber exposures have been confined to only
a few fiber types such as asbestos and man-
made vitreous fibers. Improved techniques
for characterizing human and animal
exposure to other types offibers are needed.
It is also important to note that fibers
specified by the same name are used in
numerous applications or products that
may have varying physicochemical charac-
teristics. Each fiber type, therefore, may
pose different degrees ofhealth hazard and
should not be treated as a single entity.
Moreover, fibers released into ambient air
throughout the product cycle of the fiber
can also vary greatly in size and characteris-
tics. For example, a fiber may undergo
breakage across the fiber axis, as in glass
fibers, or may generate fibrils due to split-
ting longitudinally e.g., chrysotile. Fibrils
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may also be peeled off from a core fiber
e.g., p-aramid. A fiber may undergo
structural changes during its use. For
example, RCF may partially transform
from an amorphous form into crystalline
silica after use under high-temperature
conditions. Thus, each fiber type may pose
a different nature and magnitude ofhealth
risk under different exposure conditions
e.g., workplace, user environments.
HazardEvaluation
The question of fiber fibrogenicity and
carcinogenicity in humans should be
answered within the framework ofall avail-
able evidence. Judgment about the WOE
involves consideration ofthe quality, ade-
quacy, and consistency of responses
induced by the fiber in question. The ques-
tions to be asked may indude: a) Can the
fiber be inhaled and deposited in the
human lung? b) What is known about its
deposition pattern, clearance rate, reten-
tion, and translocation pathways? c) Does
the deposited fiber have certain physical
and chemical characteristics that are critical
determinants oftoxicity and carcinogenic-
ity? d) What is the degree ofevidence for a
causal relationship between chronic respi-
ratory effects in humans and fiber expo-
sure? e) Is the fiber toxic to target cells?
J) Does the fiber induce chronic inflam-
mation and/or pathological lesions in the
exposed animals after prolonged exposure
to the fiber? g) What do we know about
the toxicity and carcinogenicity potential
ofcloselyrelated fibrous particles?
Human data, when available, are
given first priority in establishing the
presence of an adverse effect in exposed
human populations and a quantitative
relationship between environmental
exposure and adverse effects. For most
fibers, there is insufficient information on
effects in humans. In such cases, hazard
evaluation relies primarily on animal
studies, most often in the rat, on the fiber
itselfor on closely related fibrous partides.
Information on fiber disposition (deposi-
tion, translocation, dearance), dissolution,
biopersistence, in vitro biological activity,
and mechanistic data can provide addi-
tional insights into possible toxicity and
carcinogenicity ofa fiber.
It should be pointed out that consider-
able uncertainties exist when extrapolating
experimental findings to hazard assessment
in humans. When making such extra-
polations, one must recognize that the
qualitative and quantitative aspects offiber
deposition, retention, and clearance in
rodents are considerably different from
those in humans due to differences in the
anatomy and physiology ofthe respiratory
tract (21,22). First, the respirabiityofrats is
different from respirability in humans.
Fibers with aerodynamic diameters >3 pim
are not respirable by the rat but more than
20% ofthese fibers can be deposited in the
human lung. Second, fibrous particles are
preferentially deposited at the alveolar duct
bifurcations in rats, whereas they are
deposited mainly at the bronchiolar bifurca-
tions in humans. These differences may
contribute to the different pattern oflesions
among species. For example, asbestos causes
bronchogenic carcinomas in humans;
asbestos and other mineral fibers induce
peripheral lung tumors in rats. Hamsters, on
the other hand, seem to be more susceptible
to the development of fiber-induced
mesothelioma than lung tumors. The over-
all consequence is that inhalation studies in
rodents may not necessarily be predictive of
human toxicity and carcinogenicity.
Interpretations of animal study results
should be put into perspective with regard
to potential human hazard and risk.
There has been considerable debate
concerning the relevance ofvarious routes
ofexposure to cancer hazard assessment of
fibers in humans. The advantages and limi-
tations ofeach route ofadministration are
well recognized (23,24). Because inhala-
tion is the major route ofhuman exposure,
positive results of an inhalation study in
animals might have significant implications
for hazard and dose-response assessment in
humans. This finding would be bolstered
by positive results from studies using
nonphysiological routes ofadministration
such as intratracheal instillation (IT),
intrapleural inoculation or implantation,
and ip injection.
On the other hand, lack oftumorigenic
responses in an inhalation study does not
necessarily mean that the fiber is non-
hazardous to humans, because ofspecies
differences in the respirability and suscepti-
bility between humans and rodents as dis-
cussed above. Such a finding, however,
would strongly indicate that the fiber does
not exhibit carcinogenic potential in
humans ifitwas demonstrated that the tar-
get tissues (i.e., the lung) were exposed to
sufficient quantities of critical-size fibers
compared with a positive control (e.g.,
asbestos). Evidence for the absence of car-
cinogenic potential ofthe fiber in humans
must be corroborated by consistent lack of
biological and toxicological effects from
other studies.
Studies using instillation or injection
methods ofadministration are ofconsider-
able value for the evaluation ofthe poten-
tial human hazard offibers. Positive results
in instillation or injection studies would
suggest a potential hazard to humans, but
further investigation would be needed for a
firm evaluation ofthe inhalation hazard for
humans. However, a negative result in such
studies would suggest that the fiber proba-
bly is oflow human hazard potential and
the need for additional inhalation testing
would be mitigated. An exception to this
would be for fibers that have the ability to
agglomerate (certain organic fibers such as
p-aramid) and tend to reduce the actual
number ofsingle fibers at target tissues.
Dose-Response w rapolaton
To more accurately predict and characterize
human health risks from inhaled fibers, it is
necessary to understand the mechanistic
linkage between fiber exposure and bio-
logically effective dose and between the
biologically effective dose and response.
Currently, validated biologically based
models and mathematical models describing
fiber exposure/dose-response relationships
for fiber-induced toxicity and carcinogenic-
ity in quantitative terms are not yet avail-
able. There is still a lack ofinformation on
the disposition of inhaled fibers both in
laboratory animals and humans. Moreover,
the knowledge ofhow fibers cause biologi-
cal and pathological effects is still incom-
plete, and the question ofhow long a fiber
has to persist in the target tissue to induce
a biologic and pathologic response has yet
to be fully investigated. Given the incom-
plete knowledge of fiber toxicology, the
U.S. EPA often uses fiber exposure con-
centration as a surrogate for dose for risk
assessment purposes.
There are other uncertainties associated
with performing fiber exposure/response
assessments when animal data are used. A
number ofscientific judgment and science
policy choices must be made concerning the
relevance ofthe animal model to humans
and the appropriateness ofextrapolating
results from high experimental exposure to
relativelylowoccupational and environmen-
tal exposures. The rat inhalation model is
generally accepted as suitable for establish-
ing the exposure/response relationship, in
spite ofknown limitations. An exception to
this would be cases where available data
indicate that other animal species may be
more sensitive (e.g., the hamster is more
susceptible to RCF-induced carcinogenicity
of the pleura than the rat). This policy
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position is considered reasonable because it
is assumed that humans are at least as
innately sensitive as the most sensitive
species tested. Furthermore, there is
evidence that the rat inhalation model may
underestimate the risk in humans, especially
for mesotheliomas (3).
Dose-response assessment for fiber-
induced respiratory noncancer toxicity uti-
lizes the uncertainty factor approach. This
approach assumes that a safe exposure level
exists, i.e., at exposures below the thresh-
old, clinical manifestations ofpulmonary
fibrosis or pleural changes are unlikely. It
involves the identification ofthe highest
fiber exposure concentration at which there
are no statistically or biologically signifi-
cant increases in the frequency or severity
ofadverse effects between the exposed pop-
ulation and its appropriate control, and is
known as the no observed adverse effect
level (NOAEL). To conclude that a partic-
ular effect is adverse requires sound profes-
sional judgment and a clear articulation of
the scientific rationale. Because a fiber may
elicit more than one end point, the critical
end point used in the dose-response assess-
ment is the effect with the lowest NOAEL.
With regard to dose-response assess-
ment for carcinogenic effects of inhaled
fibers, a linear, nonthreshold dose-response
approach is generally used. This assump-
tion is based on the current knowledge
that asbestos fibers can influence the car-
cinogenic process at either early or late
stages by both genetic and epigenetic
mechanisms (25). However, a nonlinear
threshold approach may be appropriate if
there is sufficient evidence to support the
mode ofaction ofcertain fibrous particles
having a threshold, e.g., if the fiber-
induced carcinogenesis is a secondary
effect offibrosis/scarring, which itself is a
threshold phenomenon.
Risk Assessment of New
Fibrous Substances
underTSCA
Section 5 ofTSCA requires anyone who
intends to manufacture or import into the
United States a chemical substance not on
the TSCA inventory and not exempted
from TSCA, to submit a formal notice
known as the premanufactured notice
(PMN) to the U.S. EPA. The U.S. EPA is
required to review each PMN and make a
decision within 90 days about potential
risk to human health and environment of
allowing the manufacture, import, process-
ing, distribution, use, and disposal of
that chemical.
Risk assessment ofnew fibers is generally
hampered bylack ofinformation submitted
in the PMN, as the submitter is not
required to generate toxicologic informa-
tion on the new fibrous substance. As a
result, the U.S. EPA/OPPT relies on the
hazard and exposure information submitted
(ifany) and on readily available toxicologic
and epidemiologic data on related fibrous
substances to make a scientific judgment of
whether the new fiber may present sig-
nificant risk to human health or the envi-
ronment. Thus, risk assessments of new
fibers may be based almost entirely on
current scientific knowledge about critical
determinants of fiber toxicity and car-
cinogenicity, surrogate dose response and
exposure data, and policy assumptions.
A regulatory decision is subsequently
made either to drop the case from further
consideration or take control action to pro-
tect against that risk. If it is determined
that the fiber is of concern but there are
insufficient data to assess the potential
health effects of the fiber, control action
may be imposed until additional informa-
tion is obtained. As more information
becomes available, the risk assessment is
updated and risk management action is
adjusted if deemed necessary. Screening-
level testing may be imposed on a new
fiber of low health concern if it is to be
produced in large quantities and widely
used in commercial products, which could
result in substantial human exposure.
Testing requirements are considered neces-
sary to ensure that the new fiber does not
pose significant risk to exposed humans.
For fibers determined to be potentially haz-
ardous, the agency may issue a significant
new use rule (SNUR) to prevent the fibers
from reentering commerce without U.S.
EPA notification.
HazardIdenfication
Key factors that are generally considered in
predicting the health hazard potential of
inhaled fibers are: a) the ability ofthe fiber
to generate airborne respirable partides; b)
the fiber size distribution of the airborne
fibers; c) the morphologic and chemical
characteristics ofthe fiber; d) the in vitro
solubiity ofthe fiber; e) the biopersistence
ofthe fiber in the lung;f) the ability ofthe
fiber to cause cytoxicity, cell proliferation,
chromosomal damage, and other biological
endpoints in in vitro and in vivo assays;
g) the ability ofthe fiber to cause patholog-
ical changes in short term or lifetime
studies in laboratory animals by inhalation,
IT, and/or ip injection; and h) the toxicity
and carcinogenicity profiles ofchemically
and structurally related fibrous particles.
In the absence of any toxicologic
information, a new fibrous material is pre-
sumed to pose a fibrogenic hazard if it is
respirable. Ifthe new fiber also contains a
significant proportion of particles with a
long, thin, fibrous shape (fiber diameter
< 1 pm and fiber length 210 pm), it is
considered potentially fibrogenic and car-
cinogenic. This science policy position is
justified, as fiber dimension is an impor-
tant determinant offiber toxicity and car-
cinogenicity. Health concerns about
potential carcinogenic and fibrogenic
effects ofa fiber increase ifavailable infor-
mation indicates that it is relatively insol-
uble in physiological systems and
biopersists in the lung. The concern is
heightened if chemically and structurally
related fibrous substances are known to
cause in vitro and in vivo toxicity in short-
term studies and/or carcinogenicity in
long-term studies.
A fiber is not considered a significant
hazard to human health ifavailable infor-
mation indicates that the fiber is nonres-
pirable or has a low degree ofrespirability.
A respirable fiber may be of low health
concern ifthe fiber is relatively short, does
not biopersist in the lung, is relatively solu-
ble, exhibits low biological and toxicologic
effects in in vitro and in vivo short-term
studies, and/or demonstrates a lack of
fibrogenic and carcinogenic effect in long-
term animal studies. Some short fibers may
be fibrogenic at high exposure levels but
may not be carcinogenic. On the other
hand, a carcinogenic fiber is also likely to
be fibrogenic.
The minimum data set required by the
agency for a screening-level determination
ofpotential health hazards of a new fiber
should include a complete physical and
chemical characterization of the fiber and
the results from a well-designed and well
conducted 90-day subchronic inhalation
study in the rat. Other toxicologic infor-
mation such as in vitro solubility, in vitro
cellular assays (e.g., cytotoxicity, genotoxi-
city, cell proliferation, or generation of
ROS), and lifetime IT or ip carcinogenic-
ity studies, are considered highly relevant
and desirable in the evaluation of the
potential hazard of the fiber. However, at
the present time, these studies are not part
of the regulatory testing requirement for
new fibers. The U.S. EPA is in the process
of developing fiber toxicity and carcino-
genicity testing guidelines for new and
existing fibers (24).
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Dose-ResponseAssessment
For new fibers, it is preferable to conduct
dose-response assessments using data from
well-conducted lifetime inhalation studies
in laboratory rodents. However, toxico-
logic information on new fibers is often
lacking. Dose-response risk assessments for
chronic respiratory noncancer toxicity of
new fibers are generally based on animal
data from the most closely related fibrous
particles. Cancer risk assessment of new
fibers, on the other hand, is based primar-
ily on unit risk estimates derived from epi-
demiologic studies of asbestos workers.
This approach is considered valid only if
the fibers under evaluation do not differ
greatly from those ofasbestos in terms of
fiber morphology, dimensions, and bioper-
sistence. However, because most fibers dif-
fer widely in their physical and chemical
characteristics, this approach may overesti-
mate or underestimate the cancer risk of
the fibers under evaluation. This uncer-
tainty is taken into consideration in the
risk characterization step ofthe risk assess-
ment process. Therefore, these types of
assessments are considered screening level
and often onlyqualitative in nature.
ExposureAssessment
The first step in exposure assessment is the
evaluation ofthe life cycle ofthe fiber (how
the fiber is manufactured, processed, used,
removed, and disposed of) and the identi-
fication of any points in the product life
cycle that may result in human exposure
by inhalation in the occupational setting,
as an end user, or from environmental
releases. This is followed by the estima-
tion of the population, frequency, and
magnitude of exposure for each potential
exposure scenario, and an evaluation of
any alterations in the physical and chemi-
cal characteristics of the fiber throughout
its life cycle. This is important because
the physicochemical properties of the
fiber are major determinants of toxicity
and carcinogenicity.
A major source of uncertainty in the
assessment ofanticipated human exposure
to new fibers is the absence ofmonitoring
data on fiber exposure in the workplace,
during use, and from environmental
release. As a result, compliance with the
permissible exposure limit for respirable
nuisance dust (5 mg/m3 as an 8-hr time-
weighted average, set by the Occupational
Safety and Health Administration) is gen-
erally assumed. Considerable uncertainties
also exist for the conversion ofgravimetric
concentration into fiber concentration.
RiskCharacterization
Riskcharacterization includes an integrative
analysis of hazard, dose response, and
exposure assessments to characterize the
risk posed by a fiber throughout its
expected product life cycle. Major results
of the risk assessment are presented in a
risk characterization summary. The
summary generally includes a) the qualita-
tive WOE conclusions as to the likelihood
that the new fiber may pose a hazard to
human health; b) a discussion of the
dose-response information considered in
the assessment ofrisk from chronic respira-
tory toxicity and carcinogenicity; c) esti-
mates of the nature and extent of the
exposure, and the number and types of
people exposed; d) a conclusion with
regard to the nature and extent ofthe risk;
and e) a discussion of the overall confi-
dence and uncertainty in the analysis,
including the major assumptions made, the
scientific judgments employed, and the
degree ofconservatism involved.
In the integrated analysis for noncancer
respiratory effects, a margin of exposure
(MOE) analysis is derived to determine
the likelihood of a health risk. MOE is
defined as the ratio ofthe NOAEL divided
by the estimated human exposure ofinter-
est. When MOE is equal to or greater than
the product of uncertainty factors (UFs)
and a modifying factor (MF), the need for
regulatory concern is likely to be small.
UFs are used to account for interspecies
variation in sensitivity and intraspecies
extrapolation, and an MF is used to
account for the completeness of the data
base. With regard to cancer risk assessment
ofinhaled fibers, an excess lifetime cancer





Few risk assessments have been conducted
to date on existing fibrous substances listed
on the TSCA inventory. The scope and
depth ofthe risk assessments vary depend-
ing on the regulatory purposes. Testing
action, significant new use rulemaking,
identification ofpotential candidates for




Section 4 ofTSCA gives the U.S. EPA the
authority to gather information about toxi-
city ofexisting chemicals and the extent to
which humans are exposed to them ifthe
agency determines that insufficient data
exist to evaluate risks to human health or
the environment. Testing action can be
triggered if the fiber is produced in
substantial quantities and ifone ofthe fol-
lowing applies: a) the fiber enters the envi-
ronment in substantial quantities, b) there
is substantial human exposure (number of
people exposed), or c) there is significant
human exposure (magnitude of exposure).
Testing action can also be supported if
there is evidence to indicate that the chem-
ical may present an unreasonable risk to
human health or the environment.
U.S. EPA investigators believe that
there are sufficient reasons, based on haz-
ard information, to suspect possible health
effects from long-term inhalation exposure
to respirable fibers. Therefore, the agency
has added a respirable fibers category as a
priority substance for hazard and exposure
testing on the U.S. EPA's Master Testing
List (26).
To date, the agency has taken testing
action on only one class of fibers. The
agency has concluded that RCF is likely to
be carcinogenic and fibrogenic, but expo-
sure data are inadequate to determine if
RCF poses an unreasonable risk to workers
(27). Consequently, the U.S. EPA and the
manufacturers of RCF developed an expo-
sure monitoring program pursuant to an
enforceable consent order to obtain addi-
tional worker data (28). The agency is
presently developing guidelines for chronic
toxicity and carcinogenicity testing for
fibrous particles (24).
The objective of risk assessment in
support oftesting action is to determine if
the available data indicate a potential
health hazard and the extent of human
exposure, and if the information is
sufficient to perform a quantitative risk
assessment to justify risk reduction actions.
Thus, risk assessment in support oftesting
action generally includes only two
components: a hazard assessment and an
exposure assessment.
The hazard assessment involves an
in-depth review and evaluation of health
effects data available in the open literature
and/or directed to the U.S. EPA via TSCA
submissions. The questions to be asked are:
a) On the basis of available information,
what can be concluded about the carcino-
genic and fibrogenic potential of the fiber
under review? b) Are the available data
adequate for hazard characterization and
dose-response assessment? The types of
scientific information used in the hazard
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evaluation are similar to those discussed in
the section on new fibers. The evaluation
includes a qualitative WOE conclusion as
to the likelihood that the fiber may pose a
hazard to human health, identification of
data gap, ifany, and recommendations for
tests to fill the data gap.
The purpose ofthe exposure assessment
is to estimate the nature and extent of
human exposure to the fiber ofinterest and
to determine whether the available expo-
sure information is adequate for assessing
potential health risk. The exposure assess-
ment indudes consideration ofthe product
cycle for the fiber, estimates ofthe size and
nature ofthe populations exposed to the
fiber, and the source, magnitude, frequency,
and duration ofinhalation exposure to the
fiber, based on available monitoring or
modeling results. A discussion ofthe confi-




The technical support for a SNUR involves
an in-depth hazard assessment similar to
that used in support oftesting actions. The
U.S. EPA has promulgated a SNUR under
section 5(e) ofTSCA for erionite (29) and
issued a proposed SNUR for RCF (28) on
the basis that these fibers are hazardous to
human health, and any use ofthese fibers
may result in significant human exposure.
The SNUR would allow the U.S. EPA to
evaluate the intended new use and, if
necessary, to prohibit or restrict that activ-
ity ifsuch use would pose an unreasonable
risk to human health.
AssesmentforPrioritySetting
The U.S. EPA is developing a screening
assessment to identify fibers ofhigh con-
cern for control action. The assessment
entails a review ofreadily available hazard
and exposure data from reliable sources to
make a qualitative judgment regarding the
nature and magnitude ofpossible health
risk. The scope and depth of the assess-
ment is comparable to the assessment for
new fibers. The assessment may be based
on surrogate dose response and exposure
data and on policy assumptions. Outcomes
ofthe review may include withdrawal from
the review process because oflow hazard
concern and/or limited exposure potential,
recommendation for additional informa-
tion, and a need for more in-depth review
for risk reduction action.
AssessmentforRisk
ReductionAction
A comprehensive risk assessment is
considered necessary to support an unrea-
sonable risk finding before any risk reduc-
tion action is enacted under section 6 of
TSCA. To date, the U.S. EPA/OPPT has
conducted no comprehensive risk assess-
ments on any existing fibers except
asbestos. A comprehensive assessment ofa
fiber such as asbestos entails a critical
analysis of all relevant hazard, dose
response, and environmental exposure
data, and an assessment of quantitative
expression ofcancer risk (4).
Conclusions
Risk assessment is the starting point for
risk management consideration and the
foundation for regulatory decisionmaking.
Risk assessment approaches used by the
U.S. EPA to support regulatory decisions
under TSCA for naturally occurring and
synthetic fibers differ, depending on
whether the fiber in question is an existing
or a new fiber. This is due to differences in
the purpose ofthe assessment, the avail-
ability ofdata, time, and resources, and the
intended nature ofregulatory action.
Risk assessments of new and existing
fibers are prone to uncertainties because
health hazard and human exposure
information is incomplete for most fibers.
Furthermore, how fibers cause diseases and
what specific determinants are critical to
fiber-induced toxicity and carcinogenicity
are still not completely understood. Of
necessity, many default assumptions
bridge both data and knowledge gaps.
Further research to improve our know-
ledge base in fiber toxicology and
additional toxicity and exposure data
gathering are needed to more accurately
characterize the health risks from exposure
to inhaled fibers.
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